Frequency Therapeutics (KRRO) financial statements
Frequency Therapeutics reported revenue of $6M in fiscal 2025, down 22.3% a year over 6 years.
Net income was -$117M.
Free cash flow was -$79M.
The diluted share count rose 1237% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Frequency Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $29M | $37M | $14M | $0 | $0 | $2M | $6M |
| Research and development | $12M | $12M | $19M | $37M | $61M | $42M | $57M | $64M | $66M |
| Selling, general and admin | $4M | $7M | $15M | $27M | $37M | $17M | $27M | $31M | $28M |
| Operating income | -$16M | -$19M | -$21M | -$28M | -$84M | -$59M | -$85M | -$92M | -$122M |
| Interest expense | — | — | — | $0 | $764,000 | $961,000 | — | — | — |
| Pre-tax income | — | — | -$19M | -$26M | -$85M | -$58M | -$81M | -$83M | -$117M |
| Income tax | — | — | $0 | $35,000 | $15,000 | $10,000 | $27,000 | $141,000 | $637,000 |
| Net income | -$20M | -$19M | -$19M | -$27M | -$85M | -$58M | -$81M | -$84M | -$117M |
| EPS (diluted) | -$28.79 | -$12.53 | -$2.29 | -$0.82 | -$2.47 | -$227.42 | -$53.08 | -$9.37 | -$12.48 |
| Diluted shares | 1M | 2M | 9M | 32M | 34M | 0M | 2M | 9M | 9M |
| Operating margin | — | — | -71.4% | -74.5% | -597.3% | — | — | -4047.1% | -1906.4% |
| Net margin | — | — | -64.8% | -71.7% | -602.0% | — | — | -3680.4% | -1834.5% |
Balance sheet
Fiscal years, from Frequency Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | — | $42M | $217M | $220M | $131M | $55M | $166M | $126M | $75M |
| Total current assets | — | $43M | $221M | $225M | $135M | $57M | $173M | $132M | $82M |
| Property, plant and equipment | — | $2M | $2M | $7M | $6M | $10M | $16M | $28M | $8M |
| Total assets | — | $45M | $223M | $265M | $185M | $74M | $222M | $226M | $114M |
| Total current liabilities | — | $4M | $53M | $27M | $11M | $9M | $19M | $15M | $12M |
| Long-term debt | — | $349,000 | $180,000 | — | — | — | — | — | — |
| Total liabilities | — | $4M | $56M | $72M | $55M | $9M | $52M | $66M | $62M |
| Shareholders' equity | -$30M | -$48M | $167M | $192M | -$42M | -$99M | $170M | $160M | $51M |
| Net debt | — | -$42M | -$200M | -$220M | -$79M | -$26M | -$166M | -$56M | -$22M |
Cash flow
Fiscal years, from Frequency Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15M | -$17M | $34M | -$45M | -$76M | -$54M | -$67M | -$60M | -$79M |
| Capital spending | $2M | $436,000 | $1M | $7M | $3M | $5M | $8M | $18M | $518,000 |
| Free cash flow | -$16M | -$17M | $33M | -$52M | -$79M | -$59M | -$75M | -$78M | -$79M |
| Stock-based compensation | $91,000 | $455,000 | $4M | $10M | $22M | $20M | $2M | $4M | $8M |
| Net borrowing | — | — | — | $15M | — | — | — | — | — |
| Free cash flow margin | — | — | 114.5% | -140.2% | -561.4% | — | — | -3433.6% | -1237.2% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for KRRO.
Open KRRO in InvestinglyQuestions
What was Frequency Therapeutics's revenue in 2025?
$6M in fiscal 2025, from its 10-K filing.
How much free cash flow does Frequency Therapeutics generate?
-$79M in fiscal 2025 (operating cash flow minus capital spending).
From Frequency Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.